Merck Sees No Need To Change Strategy On Mergers

Many Vioxx scientists and sales force members will be re-deployed to other projects at Merck, company says. Withdrawal does not change the company's strategy of avoiding mega-mergers, CEO Gilmartin says. Company expects earnings per share shortfall of 50¢ to 60¢, but expects to maintain its current dividend.